Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON36826
NL-OMON36826
Completed
Not Applicable

[11C]Erlotinib pharmacokinetics: an in vivo study using positron emission tomography in non-small cell lung cancer patients with and without erlotinib therapy. - [11C]erlotinib kinetics in NSCLC with and without erlotinib

Vrije Universiteit Medisch Centrum0 sites10 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionslung cancernon-small cell lung carcinoma10038666

Overview

Phase
Not Applicable
Status
Completed
Enrollment
10
OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational invasive

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •Patients with NSCLC, planned to receive erlotinib for therapy will be included in this study.
  • •Patients age: between 18 and 70 years
  • •Life expectancy of at least 12 weeks
  • •Malignant lesion of at least 1\.5 cm diameter within the chest as measured by CT
  • •Performance status Karnofsky index \>60%
  • •Written informed consent

Exclusion Criteria

  • •Claustrophobia
  • •Pregnant or lactating patients
  • •Metal implants in the thorax (e.g. pacemakers), interfering with PET/CT imaging
  • •Concurrent treatment with experimental drugs

Investigators

Similar Trials

Not yet recruiting
Not Applicable
[11C]Erlotinib in non-small cell lung cancer patients with and without erlotinib therapy.on-small cell lung cancer NSCLCNiet-kleincellig longkanker
NL-OMON28948VU University Medical Center10
Completed
Not Applicable
Efficacy and pharmacokinetics study of erlotinib in patients with non-small cell lung cancerAdvanced non-small cell lung cancer
JPRN-UMIN000012862Shizuoka cancer center70
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)
IRCT20200105046010N46Actero Pharma. Co.24
Recruiting
Not Applicable
Imaging of [11C]erlotinib pharmacokinetics in non small cell lung cancer patients; an in vivo study with positron emission tomographylung cancer10038666
NL-OMON32923Vrije Universiteit Medisch Centrum10
Recruiting
Not Applicable
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)Bio equivalence test.
IRCT20200105046010N51Abidi Pharmaceutical Company24